[The depot neuroleptic agent fluspirilene (author's transl)].
D001480:Basal Ganglia Diseases / Q000139:chemically induced; D001794:Blood Pressure / Q000187:drug effects; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D005260:Female; D005464:Fluorobenzenes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005476:Fluphenazine / Q000008:administration & dosage / Q000627:therapeutic use; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D010302:Parkinson Disease, Secondary / Q000139:chemically induced; D010880:Piperidines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000097:blood / Q000188:drug therapy*; D013141:Spiro Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D014149:Tranquilizing Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D005464:Fluorobenzenes; D010880:Piperidines; D013141:Spiro Compounds; D014149:Tranquilizing Agents; D005476:Fluphenazine
Das Depotneurolepticum Fluspirilen. Klinische Prüfung im offenen Versuch und als Doppelblindstudie im Vergleich zu Fluphenazin-Decanoat